PharmaAI Helped Build a Personalized Cancer Vaccine. It Just Passed Phase 3
A personalized mRNA vaccine, designed with help from an algorithm, met its main goals in a Phase 3 melanoma trial run by Merck and Moderna.
Pharma · Company
Merck
Covered since Most recent
Merck, in collaboration with Moderna, has successfully completed a Phase 3 trial for a personalized mRNA cancer vaccine, which was developed using artificial intelligence. The vaccine met its primary endpoints in the trial focused on melanoma.
0Stories
+0 in the last 30 days
0Deployments tracked
Latest: Aug 19, 2026
1,137patients enrolled
Latest tracker entry
Deployments
In the tracker →- intismeran autogene
pilot1,137 cancer therapy
Stories
1 storyPharma
